N

Nkarta
D

NKTX

2.99000
USD
0.38
(14.34%)
مغلق
حجم التداول
39,442
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
211,000,574
أصول ذات صلة
    A
    ADCT
    -0.27000
    (-10.19%)
    2.38000 USD
    A
    ASND
    2.160
    (1.74%)
    126.510 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    I
    IOVA
    -0.40000
    (-4.65%)
    8.19500 USD
    M
    MGNX
    -0.23000
    (-6.04%)
    3.58000 USD
    N
    NKTR
    -0.11000
    (-9.36%)
    1.06500 USD
    المزيد
الأخبار

العنوان: Nkarta

القطاع: Healthcare
الصناعة: Biotechnology
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.